Literature DB >> 20333502

[Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].

A R Haug1, G Assmann, C Rist, R Tiling, G P Schmidt, P Bartenstein, M Hacker.   

Abstract

PURPOSE: The immunohistochemical expression of somatostatin receptor (SSTR) subtype 2 was compared to quantitative (68)Ga-DOTATATE PET in neuroendocrine tumors (NET).
MATERIAL AND METHODS: In 27 patients suffering from metastatic NET the expression of somatostatin receptors (SSTR, score 0-3) and the Ki-67 index were assessed. The immunohistochemical findings were compared with the (68)Ga-DOTATATE PET uptake in these tumors using the SUV(max) (standardized uptake value). Both values were compared with the Ki-67 proliferation index.
RESULTS: The SUV(max) in NET without SSTR expression was significantly lower compared to those with SSTR expression (p <0.05), even though 3 out of 5 NETs with a score of 0 showed a high uptake of (68)Ga-DOTATATE. The SUV(max) correlated significantly (r=0.40, p <0.05) with the score of immunohistochemical SSTR expression (negative, score 0, moderate, score 1 and high, scores 2 and 3). The Ki-67 index correlated inversely with the SSTR expression score (r=-0.42, p <0.05), but not significantly with the SUV(max) (r=-0.33, p=0.11).
CONCLUSION: (68)Ga-DOTATATE uptake was moderately correlated with the results of immunohistochemical SSTR analyses. However, SSTR negative NET may show high uptake of (68)Ga-DOTATATE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333502     DOI: 10.1007/s00117-009-1972-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  21 in total

1.  Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.

Authors:  M Papotti; M Bongiovanni; M Volante; E Allìa; S Landolfi; L Helboe; M Schindler; S L Cole; G Bussolati
Journal:  Virchows Arch       Date:  2002-03-23       Impact factor: 4.064

2.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

3.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

Authors:  Françoise Montravers; Dany Grahek; Khaldoun Kerrou; Philippe Ruszniewski; Virginie de Beco; Nicolas Aide; Fabrice Gutman; Jean-Didier Grangé; Jean-Pierre Lotz; Jean-Noël Talbot
Journal:  J Nucl Med       Date:  2006-09       Impact factor: 10.057

5.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

6.  99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Authors:  C Decristoforo; S J Mather; W Cholewinski; E Donnemiller; G Riccabona; R Moncayo
Journal:  Eur J Nucl Med       Date:  2000-09

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.

Authors:  Etienne Garin; Florence Le Jeune; Anne Devillers; Marc Cuggia; Anne-Sophie de Lajarte-Thirouard; Catherine Bouriel; Eveline Boucher; Jean-Luc Raoul
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 9.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  10 in total

1.  Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.

Authors:  Daniel Kaemmerer; Maria Athelogou; Amelie Lupp; Isabell Lenhardt; Stefan Schulz; Peter Luisa; Merten Hommann; Vikas Prasad; Gerd Binnig; Richard Paul Baum
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

2.  [Gastroenteropancreatic endocrine tumors].

Authors:  C Schmid-Tannwald; C M Schmid-Tannwald; M F Reiser; F Berger
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 3.  [Early endocrine neoplasia of the pancreas].

Authors:  V Fendrich; D K Bartsch
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

4.  [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine].

Authors:  A R Haug; P Bartenstein
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

5.  Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas.

Authors:  Christine Schmid-Tannwald; Christoph M Schmid-Tannwald; John N Morelli; Ralph Neumann; Alexander R Haug; Nathalie Jansen; Konstantin Nikolaou; Nicolai Schramm; Maximilian F Reiser; Carsten Rist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-05       Impact factor: 9.236

6.  Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.

Authors:  Philippe Thuillier; David Bourhis; Jean Philippe Metges; Romain Le Pennec; Karim Amrane; Ulrike Schick; Frédérique Blanc-Beguin; Simon Hennebicq; Pierre-Yves Salaun; Véronique Kerlan; Nicolas Karakatsanis; Ronan Abgral
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

7.  Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.

Authors:  Dominik Berzaczy; Chiara Giraudo; Alexander R Haug; Markus Raderer; Daniela Senn; Georgios Karanikas; Michael Weber; Marius E Mayerhoefer
Journal:  Clin Nucl Med       Date:  2017-09       Impact factor: 7.794

8.  Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms.

Authors:  Susanna Majala; Tiina Vesterinen; Hanna Seppänen; Harri Mustonen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Jukka Kemppainen; Johanna Arola; Saila Kauhanen
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

9.  The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors.

Authors:  Fuad Novruzov; Aziz Aliyev; Ming Young S Wan; Rizwan Syed; Elnur Mehdi; Irada Aliyeva; Francesco Giammarile; Jamshed B Bomanji; Irfan Kayani
Journal:  Eur J Hybrid Imaging       Date:  2021-05-24

10.  Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.

Authors:  Daniel Kaemmerer; Tina Träger; Maike Hoffmeister; Bence Sipos; Merten Hommann; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  Oncotarget       Date:  2015-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.